This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Closing the offices will impact efforts to improve the health of underserved pat...
Airna will use the Series B round to launch a Phase 1/2 trial of its lead progra...
Marks’ resignation leaves the field without a regulator many view as “integral” ...
The drug discovery company, which has partnerships with Eli Lilly and Novartis, ...
Shares in Moderna, Vaxcyte, Novavax and BioNTech all fell Monday after Peter Mar...
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at red...
Accelerate biomarker research with high-quality, expert-curated data to drive pr...
In his resignation letter, Marks cited disagreement with HHS Secretary Robert F....
The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for ...
Pluvicto can now be used before chemotherapy to treat a kind of metastatic prost...
The new bid surpasses an offer SK Capital and Carlyle Group made last month for ...
Many HHS department heads and staff were unaware of plans to fire some 10,000 em...
Key regulators are not recommending Lilly’s Kisunla be cleared for the European ...
Novo is paying up to $1 billion for a “non-incretin” medicine that might boost W...
The share acquisition is the latest twist in a dispute between Alcon and fellow ...
The biotech is slashing a third of its workforce and more than half of its execu...
The biotech is slashing a third of its workforce and more than half of its execu...
The Food and Drug Administration will be substantially impacted, with cuts plann...
Clearance of Vykat unlocks what analysts anticipate will be a lucrative market o...
The Johns Hopkins surgeon will helm the agency as layoffs loom and important dec...
The drug is a needed new option for treating uncomplicated UTIs, a common infect...
The Johns Hopkins surgeon will helm the agency as layoffs loom and important dec...
The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewh...
The company plans to file next year for an accelerated clearance of its "exon-sk...